Ambrx’s ARX788 gets FDA orphan drug status for gastric cancer treatment
Ambrx has announced that its antibody drug conjugate (ADC) ARX788 has been granted orphan drug designation by the US Food and Drug Administration for the treatment of patients having HER2-positive gastric cancer. The orphan drug designation for ARX788, announced in March 2021, for gastric cancer gives Ambrx with benefits such as inclusion of an exemption […]